OncoMatch/Clinical Trials/NCT05411094
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Is NCT05411094 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Durvalumab and Olaparib for locally advanced pancreatic carcinoma.
Treatment: Durvalumab · Olaparib — This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. The combination of targeted therapy with olaparib, immunotherapy with durvalumab and radiation therapy may stimulate an anti-tumor immune response and promote tumor control in locally advanced unresectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — first-line for this cancer
prior first-line chemotherapy for this cancer for at least 16 weeks without clinical, biochemical, or radiologic progression
Cannot have received: upper abdominal radiotherapy
Patients who have had prior upper abdominal radiotherapy prior to entering the study
Cannot have received: anti-PD-1/PD-L1 antibody
Patients must not have previously received anti-PD-1/PD-L1 antibodies
Cannot have received: PARP inhibitor
Patients must not have previously received ... PARP inhibitor for treatment of this cancer
Lab requirements
Blood counts
Hemoglobin >= 9.0 g/dL without blood transfusion in last 4 weeks; ANC >= 1,500/mcL; Platelets >= 100,000/mcL
Kidney function
Creatinine <= 1.5 x institutional ULN; measured creatinine clearance > 60 mL/min/1.73 m^2
Liver function
Total bilirubin <= 1.5 x institutional ULN; AST/ALT <= 2.5 x institutional ULN
Hemoglobin >= 9.0 g/dL without blood transfusion in last 4 weeks (within 2 weeks of enrollment). Absolute neutrophil count >= 1,500/mcL (within 2 weeks of enrollment). Platelets >= 100,000/mcL (within 2 weeks of enrollment). Total bilirubin <= 1.5 x institutional upper limit of normal (ULN) (within 2 weeks of enrollment). Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transferase (ALT) (serum glutamic pyruvic transaminase) [SGPT]) <= 2.5 x institutional ULN (within 2 weeks of enrollment). Creatinine <= 1.5 x institutional ULN (within 2 weeks of enrollment). Measured creatinine clearance > 60 mL/min/1.73 m^2 (within 2 weeks of enrollment).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- Los Angeles General Medical Center · Los Angeles, California
- USC / Norris Comprehensive Cancer Center · Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- University of Michigan Rogel Cancer Center · Ann Arbor, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify